Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medical device companies like CVRx generate SEC filings that reveal the operational and financial details behind their commercial expansion. For a single-product company focused on the Barostim neuromodulation system, these regulatory documents tell the story of market adoption progress.
CVRx quarterly reports (10-Q) and annual filings (10-K) break down revenue by product category and provide commentary on procedure volumes, which serve as leading indicators for Barostim market penetration. The company's filings also detail research and development spending on next-generation technology and clinical studies designed to expand the addressable patient population. Healthcare investors tracking CVRx often focus on gross margin trends as manufacturing scales and sales force productivity metrics that indicate commercial efficiency.
Form 4 insider transactions show when CVRx executives and directors buy or sell company stock. For a growth-stage medical device company, insider activity can provide signals about management confidence in the commercial trajectory. Our platform tracks these filings automatically so you can monitor executive transactions without manually checking EDGAR.
8-K material event filings capture significant CVRx announcements including earnings releases, reimbursement updates that affect market access, and clinical data that may influence physician adoption. These filings often contain information that moves the stock price before press releases are widely distributed.
Stock Titan's AI summarizes complex CVRx filings, highlighting key financial metrics, risk factors specific to medical device commercialization, and management discussion points that matter for investment analysis. Rather than reading through regulatory boilerplate, you get the substance that drives valuation.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX)52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
CVRx, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities from time to time after effectiveness. The shelf covers common stock, preferred stock, debt securities, stock purchase contracts, warrants, rights, and units, with specific terms to be set in prospectus supplements.
Offerings may be made through underwriters, dealers, agents, or directly, at fixed, market-related, or negotiated prices. Use of proceeds will be described in the applicable supplement. CVRx’s common stock trades on Nasdaq under the symbol CVRX; on November 3, 2025, the last reported sale price was $10.36 per share.
CVRx, Inc. reported third‑quarter results showing steady top‑line growth and improved margins while remaining unprofitable. Revenue for the three months ended September 30, 2025 was $14.7 million, up 10% year over year, driven mainly by U.S. heart failure implants. Gross margin rose to 87% from 83% on higher average selling prices and manufacturing efficiencies.
Operating expenses were $25.0 million, yielding a loss from operations of $12.3 million. Net loss was $12.9 million (basic and diluted net loss per share $0.49). For the nine months, revenue reached $40.6 million (up 13%) with a net loss of $41.4 million.
Cash and cash equivalents were $85.1 million as of September 30, 2025, with $50.0 million of long‑term debt outstanding under the Innovatus loan. The company issued 543,462 shares via its ATM for gross proceeds of $9.5 million during the nine‑month period. CMS finalized the 2026 Medicare Physician Fee Schedule adding Category I CPT codes for Barostim, effective January 1, 2026.
CVRx, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The disclosure was made under Item 2.02, and the press release is included as Exhibit 99.1 and incorporated by reference.
The company states this information is being furnished, not filed, under the Exchange Act. CVRx’s common stock trades on the Nasdaq Global Select Market under the symbol CVRX.
Brent Binkowski, Chief Operating Officer of CVRx (CVRX), acquired equity awards on 08/11/2025 that increase his direct stake in the company. He received 16,600 restricted stock units that vest 25% on each anniversary of the grant date, and was granted stock options for 74,900 shares with an exercise price of $7.51. The options vest 25% after one year and then 1/48th per month thereafter and have an expiration date listed as 08/10/2035. Following these transactions, the reporting person directly beneficially owns 16,600 shares and holds options for 74,900 shares.
Brent Binkowski, identified as Chief Operating Officer of CVRx, Inc. (CVRX), submitted an initial Form 3 reporting his relationship to the issuer as an officer. The Form 3 records that no securities are beneficially owned by Mr. Binkowski at the time of the reported event. The filing is an initial ownership disclosure required under Section 16 to report officers' holdings (or lack thereof).
FAQ
What is the current stock price of Cvrx (CVRX)?
What is the market cap of Cvrx (CVRX)?
